Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the development of hamartomas in multiple organs. Neurological manifestation includes cortical dysplasia, epilepsy, and cognitive deficits such as mental impairment and autism. We measured the impact of TSC2-GAP mutations on cognitive processes and behavior in, ΔRG transgenic mice that express a dominant/negative TSC2 that binds to TSC1, but has mutations affecting its GAP domain and its rabaptin-5 binding motif, resulting in inactivation of the TSC1/2 complex. We performed a behavioral characterization of the ΔRG transgenic mice and found that they display mild, but significant impairments in social behavior and rotarod motor learning. These findings suggest that the ΔRG transgenic mice recapitulate some behavioral abnormalities observed in human TSC patients.
Introduction
Tuberous sclerosis complex (TSC), first described as Bourneville's disease in the 1880s, is a genetic disorder that is manifested early in childhood. TSC is characterized by the development of hamartomas (benign tumors) and tubers in multiple organs, including the skin, retina, heart, kidney, lung, and brain (Curatolo et al., 2008) . It is postulated that the presence of these tubers in the brain contributes to the neurological abnormalities in the disease, which includes cortical dysplasia, subependymal giant cell astrocytomas (SEGA), seizures, mental impairment, attention deficit hyperactivity disorder (ADHD), and autism (de Vries et al., 2009; Orlova and Crino, 2010) . At the molecular level, deletion or genetic mutations of the tumor suppressor genes hamartin (tsc1) and tuberin (tsc2) have been identified as the cause of TSC in humans (Cheadle et al., 2000a (Cheadle et al., , 2000b . It has been reported that tsc2 gene mutations are more frequent and result in a more severe phenotype (i.e. seizures and learning disability) in TSC patients, with the exception of reported cases of patients with TSC but no mutation identified, as well as one tsc2 mutation that causes a more mild phenotype (Camposano et al., 2009; Dabora et al., 2001; Jansen et al., 2006; Kwiatkowski et al., 2003) . In addition, the tsc2 gene is more prone to large deletions, rearrangements, and missense mutations than the tsc1 gene. Of particular interest is the finding of missense mutations clustered within the tsc2 exons 34-38 which encode for a region with homology to the GAP domain of rap1GAP or GAP3 (Maheshwar et al., 1997) .
TSC2 is a GTPase-activating protein (GAP) that regulates the small G protein Rheb (Tee et al., 2003) . It forms a heterodimer with TSC1 in an interaction that confers stability to both proteins (Chong-Kopera et al., 2006; Henske, 2003; Krymskaya and Shipley, 2003; Nellist et al., 1999) . The TSC1/TSC2 heterodimer functions as a negative regulator of the protein kinase mammalian target of rapamycin (mTOR) (Fingar and Blenis, 2004; Jozwiak, 2006; Krymskaya, 2003) , a key regulator of protein synthesis that is known to be critical for synaptic plasticity and memory (Hoeffer and Klann, 2010; Richter and Klann, 2009 ). Activation of the phosphatidylinositol 3-kinase (PI3K/Akt) and extracellular signal-regulated kinase (ERK) pathways results in the phosphorylation of TSC2 and inhibition of TSC2-GAP activity, thereby increasing the levels of Rheb-GTP. This type of signaling triggers the phosphorylation of the mTOR complex 1 (mTORC1) substrates p70 S6 kinase (S6K1) and eukaryote initiation factor 4E-binding protein (4E-BP), which are key translation initiation regulators (Jozwiak et al., 2005; Orlova and Crino, 2010; Yang et al., 2006 
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